![]() |
Open for inclusion |
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patientsCancer type: Lung cancer Phase: II Principal Investigator: Helland Åslaug Country: NO Keywords: Norway, Oslo, lung, durvalumab, DART Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04392505 |